Analyst Reco. ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:02 05/12/2025 GMT			5-day change	1st Jan Change
256.55 ^USD	+2.00%		+0.28%	+12.18%

12-04	Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	MT
12-02	LivaNova PLC Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, Effective December 1, 2025	CI

Analyst Reco.

Baird Adjusts Price Target on ResMed to $300 From $320	10-31	MT
Jefferies & Co Adjusts ResMed Price Target to $285 From $290	10-31	MT
Wells Fargo Adjusts ResMed Price Target to $265 From $280	10-31	MT
Wolfe Research Adjusts ResMed Price Target to $225 From $215	10-31	MT
Morgan Stanley Adjusts ResMed Price Target to $305 From $304	10-31	MT
Mizuho Adjusts Price Target on ResMed to $300 From $310	10-31	MT
KeyBanc Adjusts Price Target on ResMed to $299 From $298	10-31	MT
RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	10-31	MT
Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	10-31	MT
Morgan Stanley Adjusts Price Target on ResMed to $304 From $298, Maintains Overweight Rating	10-21	MT
Baird Adjusts Price Target on ResMed to $320 From $305, Maintains Outperform Rating	10-15	MT
Mizuho Adjusts Price Target on ResMed to $310 From $290, Maintains Outperform Rating	10-14	MT
PolyNovo Limited Announces Appointment of Robert Douglas to the Board of Directors	10-14	CI
Analyst recommendations: Autozone, Crowdstrike, Deere & Company, Micron Technology, MongoDB...	09-18
Citigroup Initiates ResMed at Buy With $330 Price Target	09-18	MT
CICC Adjusts Price Target on ResMed to $325 From $295, Maintains Outperform Rating	08-18	MT
JPMorgan Adjusts ResMed Price Target to $310 From $290, Maintains Overweight Rating	08-01	MT
Baird Adjusts ResMed Price Target to $305 From $283, Maintains Outperform Rating	08-01	MT
UBS Adjusts ResMed Price Target to $325 From $285, Maintains Buy Rating	08-01	MT
Piper Sandler Adjusts Price Target on ResMed to $270 From $248, Maintains Neutral Rating	08-01	MT
Stifel Adjusts Price Target on ResMed to $270 From $240, Maintains Hold Rating	08-01	MT
KeyBanc Adjusts Price Target on ResMed to $298 From $274, Maintains Overweight Rating	08-01	MT
Jefferies Adjusts Price Target on ResMed to $290 From $245, Maintains Hold Rating	08-01	MT
Wolfe Adjusts Price Target on ResMed to $215 From $200, Maintains Underperform Rating	08-01	MT
Mizuho Adjusts Price Target on ResMed to $290 From $270, Maintains Outperform Rating	08-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed's innovation-driven success and prospects

October 31, 2025 at 08:55 am